Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
SyntheticMR AB is a Swedish medical technology company specializing in advanced software solutions for magnetic resonance imaging (MRI). Headquartered in Linköping, Sweden and founded in 2007, the company focuses on quantitative MRI, enabling clinicians to obtain more objective and comprehensive data from a single scan. Its core SyMRI product portfolio measures tissue properties and automatically generates multiple contrast-weighted images, quantitative maps, and biomarker segmentations from one MR sequence. Solutions such as SyMRI NEURO support brain imaging with volumetric assessments and parametric maps for neurological evaluation, while SyMRI MSK, including dedicated Spine and Knee modules, provides detailed information for musculoskeletal diagnostics. SyntheticMR AB also offers customized implementations like MAGiC, tailored to specific scanner environments. The company serves hospitals, imaging centers, and healthcare systems in markets including the United States, Japan, India, Germany, and South Korea, playing a role in improving MRI workflow efficiency and diagnostic consistency in radiology and related specialties.
kr 0.03
kr 0.00 (-4.00%)
EOD Jun 26, 2026 · Twelve Data
ROIC dropped from -13.94% to -37.55%, capital efficiency is deteriorating. Negative free cash flow of -kr 13M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 56M
Net Income (TTM)
-kr 48M
▼ -241.5% YoY
Op. Margin
-81.12%
ROIC
-37.55%
▼ -23.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 18M
▼ -28.5% YoY
Op. Cash Flow (TTM)
-kr 13M
▼ -87.9% YoY
Net Debt
-kr 7M
Net Cash Position
Cash & Equiv.
kr 7M
3Y CAGR: -1.6%
Continue Research
SyntheticMR AB (SYNT.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, SyntheticMR AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
SyntheticMR AB scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -81.1% operating margin and a -37.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh SYNT.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.